Home>Topics>>Oramed Readies Oral Insulin Study In U.S.
Oramed Readies Oral Insulin Study In U.S.
Israel Stocks News and Analysis from Seeking Alpha
Tue, 7 May 2013
By Len Zehr : Oramed Pharmaceuticals (NASDAQ: ORMP ) is awaiting a decision from the FDA, possibly later this week, to conduct a sub-study of the safety of its oral insulin candidate, ORMD-0801, before proceeding to a large, multi-center Phase 2 clinical trial later this year. "Approving a clinical ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.